Bayer AG Stock
Bayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Pros and Cons of Bayer AG in the next few years
Pros
Cons
Performance of Bayer AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bayer AG | 5.160% | 13.556% | 25.796% | 113.311% | 19.573% | -22.944% | -15.138% |
| Merck KGaA | 0.350% | 0.891% | 7.518% | -9.208% | 6.419% | -34.844% | -12.563% |
| Biogen Inc. | -2.890% | -12.120% | -2.878% | 3.392% | -5.405% | -46.830% | -37.965% |
| Johnson & Johnson | -0.190% | 7.332% | 5.850% | 31.423% | 6.676% | 17.222% | 42.080% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Bayer, with its US ticker symbol BAYZF, is a prominent player in the pharmaceuticals industry, boasting a rich history and a diverse portfolio. A deep dive into Bayer's financials reveals a complex picture—while there are some strengths and opportunities for growth, several areas raise concerns.
When analyzing Bayer's financials, several key aspects come into play, revealing both positives and negatives that deserve attention. The company's total assets stood at approximately €123.34 billion in 2023, slightly up from €124.88 billion in 2022. A noticeable highlight is Bayer’s gross profit, which peaked at around €27.8 billion in 2023, reflecting robust revenue generation capabilities even amidst some operational challenges.
*Pros: *
Comments
News
Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation
The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal
Bayer Accelerates Pharma Growth on High-Value Portfolio
On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026.
Capitalizing on new launch
Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause
Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn’t Stop for a Hot Flash’ campaign, which speaks to women with moderate to severe